Cargando…
Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effect...
Autores principales: | ASTOLFI, LAURA, GHISELLI, SARA, GUARAN, VALERIA, CHICCA, MILVIA, SIMONI, EDI, OLIVETTO, ELENA, LELLI, GIORGIO, MARTINI, ALESSANDRO |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621656/ https://www.ncbi.nlm.nih.gov/pubmed/23404427 http://dx.doi.org/10.3892/or.2013.2279 |
Ejemplares similares
-
Coenzyme Q10 plus Multivitamin Treatment Prevents Cisplatin Ototoxicity in Rats
por: Astolfi, Laura, et al.
Publicado: (2016) -
Correction: Coenzyme Q10 plus Multivitamin Treatment Prevents Cisplatin Ototoxicity in Rats
por: Astolfi, Laura, et al.
Publicado: (2017) -
Association between idiopathic hearing loss and mitochondrial DNA mutations: A study on 169 hearing-impaired subjects
por: GUARAN, VALERIA, et al.
Publicado: (2013) -
Immune Response After Cochlear Implantation
por: Simoni, Edi, et al.
Publicado: (2020) -
Liquid Crystalline Nanoparticles Conjugated with Dexamethasone Prevent Cisplatin Ototoxicity In Vitro
por: Valente, Filippo, et al.
Publicado: (2022)